Repertoire Immune Medicines
A clinical-stage biotech company decoding the immune synapse to create novel immune therapies for cancer, immune disorders, infectious disease, and other serious diseases.
The US company’s repertoire of T cell receptor antigen codes that drive health and disease represents one of the greatest opportunities for innovation in medical science.
In April 2021, Repertoire completed a $189 million Series B financing to support the broad application of its DECODE platform to define and understand the complete repertoire of T cell receptor-antigen pairs that drive cellular immunity. The insight gleaned from this information will enable a new era of new immune medicines designed to exploit these critical interactions.
Founded by Flagship Pioneering, Repertoire has raised more than $350 million in the aggregate to date.
Latest Repertoire Immune Medicines News & Features
13 April 2021
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze